The FDA has recently approved two new oral treatments for urogenital gonorrhea. But what is the data behind these approvals, and what does this mean for clinical practice? Come join this STI expert hour to learn more!
Presenter
Katherine Yang, PharmD, MPH Professor, Department of Clinical Pharmacy, University of California (UCSF) School of Pharmacy Infectious Diseases Clinical Pharmacist, UCSF Medical Center
Learning Objectives
Describe the mechanisms of action and antimicrobial activity of zoliflodacin and gepotidacin against Neisseria gonorrhoeae, including their effectiveness against drug-resistant strains
Compare the clinical efficacy, safety profiles, and potential roles of zoliflodacin and gepotidacin in the treatment of gonorrhea
STI Clinical Update Webinar – Mpox Clinical Update: What’s New, What to Suspect, What to Do – Recognition & Prevention
June 2, 2026 12:00PM-1:15 PM (PDT) 1.25 CME units offered at no cost Registration closes on June 1, 2026 at 3:00PM (PDT)
This clinician-focused webinar reviews the latest U.S. and global epidemiology of mpox, including clade I. Learn how and when to suspect, diagnose, manage, and report mpox promptly and effectively. We’ll also translate the most recent vaccine recommendations into practical workflows during Pride Season and in preparation for summer travel and events.
Presenters
Eric Tang, MD, MPH Public Health Medical Officer Office of Sexually Transmitted Infections (STIs) and Hepatitis C Virus (HCV) California Department of Public Health (CDPH) Clinical Faculty, California Prevention Training Center at UCSF
Jason Zucker, MD, MS Assistant Professor of Medicine Columbia University Irving Medical Center PI/Co-Medical Director NYC STI/HIV Prevention Training Center
Learning Objectives
Describe the latest epidemiological trends and key developments in mpox, both in the US and globally, with a particular focus on the emergence and clinical implications of clade I mpox
Identify and diagnose mpox and when to suspect clade I mpox, ensuring prompt and effective management
Integrate the most recent CDPH mpox vaccine and prevention recommendations into routine clinical practice
Strategies to Improve HIV Outcomes
Webinar Series March 3, 10, 17, & 24 12:00 – 12:45 PM PT
The goal of the 4-part webinar series, Strategies to Improving HIV Outcomes, is to strengthen the organizational capacity of health departments and community-based organizations to support comprehensive HIV programs to diagnose, treat, prevent HIV and syndemic conditions, and address social conditions affecting health. This 4-part webinar series will cover the following topics:
Using Artificial Intelligence in HIV Prevention
Strengthening Linkage to Care Activities
Strategies to Increase PrEP Uptake
Strengthening Engagement & Retention in Care
Syphilis in California: New CDPH Screening Recommendations Explained
The California Department of Public Health Office of STIs and HCV (formerly STD Control Branch) collaborated with Dr. Diana Ramos, California’s Surgeon General, to create this video. The goal is to inform health care providers of California’s syphilis screening recommendations, which were updated in October of 2024.
How to Prepare Bicillin® L-A with Lidocaine for Pain Control During Treatment for Syphilis
January 2026. Developed in collaboration with Kristin Harter, PharmD at the University of California, San Francisco, this instructional video provides step-by-step guidance for adding lidocaine to Bicillin® L-A for the mitigation of pain during treatment of syphilis. This resource is intended for healthcare professionals who provide clinical care and are involved in the preparation and administration of these medications.
Additional resources are available from our partners at the Saint Louis STI/HIV Prevention Training Center including a visual guide and printable brochure.
STI Clinical Update Webinar – HCV in 2026: A Clinical Update and Review
January 20, 2026 10:30 am -12:00 pm (PST) 1.5 CME units at no cost Please note: CME not available for viewing the recording of the webinar.
Presenters
Norah Terrault, MD, MPH, FAASLD Professor of Medicine Chief, Division of Gastrointestinal and Liver Diseases Neil Kaplowitz Chair in Liver Diseases Keck School of Medicine of USC University of Southern California
Kurtis Mohr, MD, AAHIVM Public Health Medical Officer, Office of STIs and HCV California Department of Public Health
Course Description
Co-sponsored by the California Department of Public Health and California Prevention Training Center at the University of California San Francisco, this STI Clinical Update webinar will provide a comprehensive review of hepatitis C (HCV) in 2026, focusing on clinical cases and test-to-treat models of care.
Learning Objectives
Understand and apply the test-to-treat model for hepatitis C Participants will learn how to initiate direct-acting antiviral (DAA) therapy at the point of diagnosis, including in community settings, using Dr. Terrault, AASLD or CDPH, or other simplified treatment pathways. Literature supporting the effectiveness and feasibility of test-to-treat will be reviewed.
Use case-based scenarios to identify key clinical considerations Through interactive case studies, providers will explore how to interpret relevant lab values, assess comorbidities, and evaluate potential drug interactions when initiating DAA therapy. Emphasis will be placed on practical decision-making using simplified treatment algorithms.
Implement appropriate monitoring and follow-up during hepatitis C treatment Attendees will learn recommended baseline and follow-up laboratory testing, including HCV RNA viral load timing, and understand whether there is a need for and the frequency and purpose of clinical follow-up visits throughout the treatment course.
To request an accommodation for this event, please email captc@ucsf.edu at least a week in advance of the event.
STI Expert Hour Webinar – Male Partner Treatment to Prevent BV Recurrence: Evidence and Implementation
December 18, 2025 1:30 pm – 2:50 pm (PST)
Please note: CME not available for viewing the webinar recording.
Presenter
Catriona Bradshaw, MMBS(Hons), FAChSHM, FAHMS, PhD Professor Melbourne Sexual Health Centre, Alfred Health School of Translational Medicine, Monash University Melbourne School of Population and Global Health, University of Melbourne
Course Description
This seminar will discuss the epidemiological and microbiological evidence and pilot data that led to the StepUp randomised controlled trial (RCT) – an RCT that demonstrated treating male partners with a combination of oral and topical antimicrobials at the time a women is being treated for bacterial vaginosis (BV) significantly improved cure over 12 weeks. The trial methodology and findings will be presented in detail. The seminar will have a focus on the practicalities of implementation and prescribing including examples of free online resources available to assist clinicians in discussing and providing partner treatment for BV, consumer resources to assist informed decision making, and qualitative research findings. Time will be made available for audience discussion and participation.
Learning Objectives
Participants will be able to understand the rationale and evidence for male partner treatment for BV and apply this new knowledge to their clinical practice.
Participants will be able to discuss partner treatment for BV with their patients, facilitate shared decision making, understand where to access evidence-based resources, and make informed decisions regarding the provision of this intervention for heterosexual couples.
For Patients: Ureaplasma urealyticum FAQ
Developed by the San Francisco Department of Public Health and California Prevention Training Center, this practical resource addresses frequently asked questions about the genital bacterium Ureaplasma urealyticum (UU), including:
What is UU?
Is it always harmful?
When are testing and/or treatment for UU recommended? (And when are they not?)
The goal is to help patients learn the facts about this common but often misunderstood bacterium.
Developed by the San Francisco Department of Public Health and California Prevention Training Center, this practical resource addresses frequently asked questions about the genital bacterium Ureaplasma urealyticum (UU), including:
When screening, testing, and/or treatment for UU are (and are not) recommended,
How to interpret positive test results in asymptomatic patients, and
How to approach partner management.
The goal is to help providers navigate the uncertainty around UU, avoiding unnecessary testing and treatment while ensuring appropriate treatment when indicated.
We use cookies to ensure that we give you the best experience on our website, but we also recognize the right to privacy. Please accept or disable cookies for this website.
